1. Introduction {#sec1-brainsci-08-00145}
===============

*TUBA1A* is a highly-conserved gene with few changes among eukaryotes and few polymorphic variants in human populations. *TUBA1A* encodes the tubulin alpha-1A chain, a protein that is highly-expressed in the cerebral cortex, hippocampus, cerebellum, and brainstem of the developing fetal brain, with a decrease in postnatal and adult stages \[[@B1-brainsci-08-00145],[@B2-brainsci-08-00145]\]. Alpha- and beta-tubulin subunits form dimers that coassemble into microtubules. Microtubules are dynamic polymers that perform a range of mechanical tasks within the cell. As major components of the mitotic spindle, microtubules control division of neuronal progenitors to produce neurons. In turn, they generate the push-and-pull forces that are required for the migration of primitive neurons, from deep proliferative areas to the cortical plate. Subsequently, bundles of stable and polarised microtubule polymers generate long axons facilitating cortical organisation and synaptic connectivity.

*TUBA1A* was the first tubulin gene to be associated with human brain malformations \[[@B3-brainsci-08-00145]\]. Mutations in *TUBA1A* have been reported in patients with a range of brain malformations, including lissencephaly, microlissencephaly, polymicrogyria, and simplified gyri \[[@B4-brainsci-08-00145],[@B5-brainsci-08-00145],[@B6-brainsci-08-00145]\]. They have also been reported in patients with hydranencephaly-like dysplasias, cerebral palsy, and autistic spectrum disorders \[[@B7-brainsci-08-00145],[@B8-brainsci-08-00145],[@B9-brainsci-08-00145]\]. *TUBA1A* mutations (as with other tubulinopathies) are often associated with hypoplasia/agenesis of the corpus callosum, hypoplasia/dysplasia of the cerebellum, and dysmorphic basal ganglia \[[@B5-brainsci-08-00145],[@B6-brainsci-08-00145]\]. Common clinical features in *TUBA1A* patients include microcephaly, intellectual disability, motor impairment, and epilepsy. Mutations in several other tubulin genes have been reported in patients with brain malformations including TUBB2B \[[@B10-brainsci-08-00145]\], *TUBB3* \[[@B11-brainsci-08-00145],[@B12-brainsci-08-00145]\], *TUBB* \[[@B13-brainsci-08-00145]\], *TUBB2A* \[[@B14-brainsci-08-00145]\], and *TUBG1* \[[@B15-brainsci-08-00145]\]. However, *TUBA1A* mutations remain the most common cause of tubulin-related brain malformations, with over 60 mutations being described to date \[[@B6-brainsci-08-00145]\]. Most disease-causing *TUBA1A* mutations are de novo, although familial recurrence due to parental somatic mosaicism has been reported \[[@B4-brainsci-08-00145],[@B16-brainsci-08-00145]\].

Pathogenic *TUBA1A* mutations have been found distributed throughout the gene. A handful of recurrent *TUBA1A* mutations have been reported. These include the p.(Arg402His) mutation, which has been reported in at least five patients and is associated with classic lissencephaly \[[@B3-brainsci-08-00145],[@B17-brainsci-08-00145]\]. Similarly, the recurrent p.(Arg264Cys) mutation has been found in several patients and is typically associated with central pachygyria \[[@B3-brainsci-08-00145],[@B18-brainsci-08-00145],[@B19-brainsci-08-00145]\]. Few genotype-phenotype correlations have been reported for *TUBA1A*. However, the phenotypic effects of a specific recurrent mutation are generally consistent. Alpha-tubulin must fold in a precise way and present specific shapes and charges on its surface to interact with other proteins (e.g., beta-tubulin subunits, microtubule binding proteins) and to correctly handle and hydrolyse guanosine-5′-triphosphate (GTP). Many *TUBA1A* mutations have been shown to disrupt protein folding and/or heterodimer formation, resulting in either a reduced yield or reduced stability \[[@B20-brainsci-08-00145]\].

During the clinical diagnostic work-up of two unrelated patients with developmental delay and brain abnormalities, we identified the same mutation, c.5G\>A, p.(Arg2His), in *TUBA1A*. To define the clinical consequences of this mutation, we collected detailed phenotype information from both patients and two additional patients that were previously reported in the literature \[[@B21-brainsci-08-00145],[@B22-brainsci-08-00145],[@B23-brainsci-08-00145]\]. We examined the functional impact of the mutation by in vitro microtubule studies and computer-based protein structure modeling.

2. Materials and Methods {#sec2-brainsci-08-00145}
========================

2.1. Patients {#sec2dot1-brainsci-08-00145}
-------------

Patients 1 and 2 were diagnosed during routine clinical diagnostic work-ups. Patient 1 underwent testing with a 12-gene polymicrogyria sequencing panel (targets enriched by Agilent SureSelect system, followed by Illumina sequencing) in the United States. Patient 2 had testing with a 40 gene cortical malformation gene panel (HaploPlex target enrichment system followed by Illumina sequencing) in the United Kingdom. The mutations in Patients 1 and 2 were confirmed and shown to be de novo by Sanger sequencing in the patient and both parents. Patient 3 underwent trio-based whole exome sequencing (WES) as a part of their routine clinical diagnostic work-up in the United States \[[@B21-brainsci-08-00145],[@B23-brainsci-08-00145]\]. The approach to analysis and filtering of the WES data has previously been described \[[@B21-brainsci-08-00145]\]. No other candidate variants were identified in the patient. Patient 4 underwent targeted sequencing of a panel of 423 genes that are associated with corpus callosum anomalies in France \[[@B22-brainsci-08-00145]\]. The approach to analysis and filtering of this panel has previously been described \[[@B24-brainsci-08-00145],[@B25-brainsci-08-00145]\]. No other candidate variants were identified in the patient. Consent was obtained from the parents of all the participants for publication. The genomic location of the mutation is chr12:g.49580615C\>T (GRCh37/hg19), rs587784491. Coding and protein positions of *TUBA1A* mutations are based on GenBank accession codes NM_006009.3 (ENST00000301071.7) and NP_006000.2, respectively.

2.2. Homology Modelling {#sec2dot2-brainsci-08-00145}
-----------------------

Structural predictions of wild-type and mutant TUBA1A protein subunits were generated while using a previously-described homology modeling pipeline \[[@B26-brainsci-08-00145]\]. This approach uses the solved structure of a homologous template to predict the folding of a target sequence. The target sequence was wild-type TUBA1A (NP_006000.2). The template used was the crystal structure of Tubulin alpha-1B from *Bos taurus* (Protein Data Bank (PDB): 4I4T) \[[@B27-brainsci-08-00145]\], which shares 99% sequencing identity with human TUBA1A. Microtubule architecture was based on a previously published template (PDB: 2XRP) \[[@B28-brainsci-08-00145]\]. Homology modelling was performed by MODELLER (version 9.17) \[[@B29-brainsci-08-00145]\]. Structural models were viewed and analysed while using the UCSF Chimera software (version 1.12) \[[@B30-brainsci-08-00145],[@B31-brainsci-08-00145]\].

2.3. Expression Construct Mutagenesis and Cell Culture {#sec2dot3-brainsci-08-00145}
------------------------------------------------------

A C-terminally FLAG-tagged wild-type TUBA1A expression construct (pRK5-TUBA1A-C-FLAG) was modified to generate TUBA1A-R2H by site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). HEK-293 cells were cultured in Dulbecco's modified Eagle's media (ThermoFisher, Waltham, MA, USA, catalogue number 41966029), supplemented with 10% fetal calf serum (ThermoFisher, 10500056) and 1% penicillin/streptomycin (ThermoFisher, 15070063), as previously described \[[@B14-brainsci-08-00145]\].

2.4. Immunocytochemistry {#sec2dot4-brainsci-08-00145}
------------------------

HEK-293 cells were cultured in Dulbecco's modified Eagle's media (ThermoFisher, 41966029). supplemented with 10% fetal calf serum (ThermoFisher, 10500056) and 1% penicillin/streptomycin (ThermoFisher, 15070063) and incubated at 37 °C 5% CO~2~. Cells were seeded onto poly-D-Lysine (Sigma-Aldrich, St. Louis, MO, USA, P6407) pre-coated 13 mm glass coverslips. After 24 h, the cells were transfected with either wild-type or mutant expression constructs using Lipofectamine 2000 (ThermoFisher, 11668030). Twenty-four hours post-transfection, the cells were fixed with methanol at −20 °C for five minutes. Fixed cells were blocked with blocking buffer (phosphate-buffered saline (PBS) with 2% Bovine Serum Albumin (BSA; Sigma-Aldrich, B4287) and 0.5% Triton (Sigma-Aldrich, T8787)) for 30 min at room temperature (23 °C). Cells were immunostained with rabbit anti-FLAG (Sigma-Aldrich, F7425; 1:500) and mouse anti-alpha-tubulin (Sigma-Aldrich, T6199; 1:750) diluted in PBS with 2% BSA and 0.1% Triton for one hour at room temperature. Primary antibodies were aspirated, cells washed three times with PBS, and incubated with AlexaFluor^568^-conjugated goat anti-rabbit (ThermoFisher, A11011) and AlexaFluor^488^-conjugated goat anti-mouse (ThermoFisher, A11011) secondary antibodies for 30 minutes at room temperature, and protected from light from this point onwards. Cells were rinsed with PBS, mounted onto glass slides with ProLong Gold mounting medium (ThermoFisher, P10144) and stored at 4 °C until examined by confocal microscopy (Zeiss Axioscope).

2.5. Predicting the Probability of TUBA1A Substitutions {#sec2dot5-brainsci-08-00145}
-------------------------------------------------------

The genomic DNA sequence of the *TUBA1A* gene (based on transcript ENST00000301071.7) was obtained from the Ensembl Genome Browser \[[@B32-brainsci-08-00145]\]. A sliding window was implemented using a Perl script. For each 7-nucleotide window the script recorded the position and base of the central nucleotide. The heptanucleotide sequence was then looked up in the data from \[[@B33-brainsci-08-00145]\] (Supplementary Table 7 from that paper). The substitution probabilities for changing the central nucleotide to each of the three alternative bases were taken (averaging African, Asian, and European values). The cDNA and protein consequences of each substitution were derived using Mutalyzer \[[@B34-brainsci-08-00145],[@B35-brainsci-08-00145]\]. Predicted substitution probabilities were obtained for all coding positions, introns (±20 base pairs flanking exons), and 5' and 3' untranslated regions (±20 base pairs).

3. Results {#sec3-brainsci-08-00145}
==========

3.1. Clinical Features of Patients with the p.(Arg2His) Mutation {#sec3dot1-brainsci-08-00145}
----------------------------------------------------------------

We identified two unrelated patients (Patients 1 and 2) with the same *TUBA1A* missense mutation, c.5G\>A, p.(Arg2His). A search of the literature found reports of two additional patients with the p.(Arg2His) mutation (Patients 3 and 4) \[[@B21-brainsci-08-00145],[@B22-brainsci-08-00145],[@B23-brainsci-08-00145]\]. Only brief descriptions of the two published subjects were previously available. We obtained detailed clinical information from the four individuals ([Table 1](#brainsci-08-00145-t001){ref-type="table"}, detailed case reports are provided in the [Supplementary Material](#app1-brainsci-08-00145){ref-type="app"}). All four mutations were de novo. Consistent features in the living patients were developmental delay and microcephaly. MRI brain images from Patients 1--3 were available for review ([Figure 1](#brainsci-08-00145-f001){ref-type="fig"}). The images demonstrated the hypoplasia and dysplasia of the cerebellar vermis (3/3), hypoplasia or dysgenesis of the corpus callosum (3/3), and dysmorphic basal ganglia (3/3). Patient 1 had bilateral perisylvian polymicrogyria. The pons of all three patients was small, particularly affecting the belly of the pons.

Patient 4 was a fetus terminated at 36 weeks gestation. Post-mortem examination of Patient 4 found a small brain (weight on 5th centile) with shortening of the corpus callosum and cerebellar hypoplasia ([Figure 2](#brainsci-08-00145-f002){ref-type="fig"}A,B). Neuropathology examination found bilateral perisylvian polymicrogyria ([Figure 2](#brainsci-08-00145-f002){ref-type="fig"}C--E). At the supratentorial level, callosal fibers and corticospinal tracts (CST) were hypoplastic. The brainstem was shortened and dysmorphic, displaying a Z-shaped kink. At the level of the cerebral peduncles, the CST were present but reduced in size. The pons was reduced in size in its basilar part. In the pons the CST were present at the junction with the peduncles but showed a chaotic pattern in between the pontine nuclei. The transverse pontine fibers were also reduced, and associated with cerebellar heterotopias and hypoplastic deep nuclei. At the level of the medulla, the pyramids were present but hypoplastic. The inferior olivary nuclei were also reduced in size. Neuronal heterotopia of the olivary nuclei was noted. At the cervical spinal cord level, crossing CST were absent. Cerebellar foliation was normal, but lamination was impaired with rare and misaligned Purkinje cells.

3.2. Modelling the Structural Effects of p.Arg2His {#sec3dot2-brainsci-08-00145}
--------------------------------------------------

The Arg2 residue of TUBA1A is highly conserved across species and tubulin isoforms ([Figure S1](#app1-brainsci-08-00145){ref-type="app"}). The p.(Arg2His) variant is not present in gnomAD and multiple in silico prediction tools suggest it is deleterious ([Table S1](#app1-brainsci-08-00145){ref-type="app"}). However, the physicochemical difference between arginine and histidine is relatively small (Grantham difference 29) with both of the residues having positively-charged side chains. The c.5G\>A change is predicted to have minimal effects on the splicing at the adjacent splice acceptor site ([Figure S2](#app1-brainsci-08-00145){ref-type="app"}). When incorporated into polymerised microtubule, the N-terminus of alpha-tubulin is positioned near the inter-dimer interface, between the alpha-tubulin subunit of one heterodimer and the beta subunit of the next heterodimer. To study the effects of p.Arg2His on the three-dimensional structure of the protein, we compared wild-type and mutant TUBA1A by modelling the alpha/beta-tubulin heterodimer ([Figure 3](#brainsci-08-00145-f003){ref-type="fig"}A,B) (the protein variant is given here without brackets as we know the amino acid sequence in a simulation). The effects of the mutation were mild. No predicted hydrogen bonding was lost or gained between the alpha- and beta-tubulin subunits as a result of p.Arg2His. A hydrogen bond between Arg2 and the highly-conserved Cys4 residue within TUBA1A was lost. In addition, new bonds between Glu3, and both Asn50 and Thr130 were predicted to form as a result of the substitution. Additional conformational changes were predicted to occur in a loop region (Asp38 to Asn51, [Figure 3](#brainsci-08-00145-f003){ref-type="fig"}B), which may affect interactions between heterodimers.

3.3. Heterologous Expression of TUBA1A-R2H in HEK-293 cells {#sec3dot3-brainsci-08-00145}
-----------------------------------------------------------

TUBA1A containing the p.(Arg2His) mutation (TUBA1A-R2H) was expressed in cultured HEK-293 cells. TUBA1A-R2H incorporated into the microtubule polymer network ([Figure 3](#brainsci-08-00145-f003){ref-type="fig"}C), suggesting that it successfully folds and dimerises with endogenous beta-tubulin. However, in comparison to wild-type TUBA1A ([Figure 3](#brainsci-08-00145-f003){ref-type="fig"}D), there was a slight increase in the proportion of the mutant FLAG-tagged protein seen unpolymerised within the cytosol. This suggests the mutation subtly alters the function (folding, dimerisation, or coassembly) of the subunit, but that once incorporated the dynamics of the mutant subunit are similar to wild type.

3.4. Substitution Probability of Recurrent TUBA1A Mutations {#sec3dot4-brainsci-08-00145}
-----------------------------------------------------------

The observation of p.(Arg2His) on four separate occasions suggested that it was a common recurrent *TUBA1A* mutation. However, we noted that p.(Arg2His) had not been reported in previous large tubulinopathy cohorts \[[@B6-brainsci-08-00145]\]. In contrast, several *TUBA1A* mutations have been found recurrently in tubulinopathy patients. Examples include p.(Arg214His) \[[@B6-brainsci-08-00145],[@B36-brainsci-08-00145]\], p.(Arg264Cys) \[[@B3-brainsci-08-00145],[@B18-brainsci-08-00145],[@B19-brainsci-08-00145]\], p.(Arg390Cys) \[[@B17-brainsci-08-00145],[@B37-brainsci-08-00145]\], p.(Arg402His) \[[@B3-brainsci-08-00145],[@B17-brainsci-08-00145],[@B38-brainsci-08-00145],[@B39-brainsci-08-00145]\], p.(Arg402Cys) \[[@B17-brainsci-08-00145],[@B19-brainsci-08-00145]\], and p.(Arg422His) \[[@B17-brainsci-08-00145],[@B18-brainsci-08-00145],[@B40-brainsci-08-00145]\]. This made us wonder whether p.(Arg2His) had a lower mutation rate than the other recurrent *TUBA1A* mutations or whether it was just ascertained less frequently. We observed that the recurrent mutations all occurred at CpG sites, which are prone to spontaneous deamination (CGx is the codon for arginine). This highlighted that sequence context was likely to be an important factor. To predict the substitution rates at these sites and to compare them with the rest of *TUBA1A*, we estimated the probability of all possible single-base substitutions in *TUBA1A* based on heptanucleotide context (target position and three flanking nucleotides either side). Heptanucleotide context has been shown to explain \>81% of variability in substitution probabilities \[[@B33-brainsci-08-00145]\]. We found the seven recurrent *TUBA1A* mutations all ranked in the top 1% for substitution probability. The p.(Arg2His) mutation was the second highest in the group (ranking 7th out of 4548 possible substitutions) ([Table S2](#app1-brainsci-08-00145){ref-type="app"}). These results suggest p.(Arg2His) has a mutation rate that is similar to other recurrent *TUBA1A* mutations. The lack of observations in previous tubulinopathy cohorts may therefore reflect differences in ascertainment.

4. Discussion {#sec4-brainsci-08-00145}
=============

In this report, we describe four patients with the TUBA1A p.(Arg2His) mutation. The patients had similar phenotypes with mild variability. Shared features included developmental delay, microcephaly, hypoplasia, and dysplasia of the cerebellar vermis, dysplasia or thinning of the corpus callosum, and dysmorphic basal ganglia. The pons tended to be small, disproportionally affecting the belly of the pons. We suspect the pons is dyspastic (i.e., abnormally developed) as well as small. Histopathological abnormalities of the pons were noted in patient 4. Two of the patients had bilateral perisylvian polymicrogyria. These features are typical of a tubulinopathy spectrum disorder \[[@B6-brainsci-08-00145]\]. Our findings suggest that p.(Arg2His) is a common recurrent *TUBA1A* mutation. Tubulinopathy patients are often ascertained due to cortical malformations (e.g., the classical lissencephaly associated with the recurrent p.(Arg402His) mutation)). In contrast, p.(Arg2His) does not cause an extensive cortical malformation. This may explain why p.(Arg2His) has not been observed in previous tubulinopathy cohorts \[[@B6-brainsci-08-00145]\].

Phenotypic variability that is associated with recurrent *TUBA1A* mutations has previously been noted. For example, the p.(Arg390Cys) mutation was first reported in a patient with mild gyral simplification, complete agenesis of the corpus callosum, and cerebellar hypoplasia \[[@B17-brainsci-08-00145]\]. It was subsequently reported in a patient with asymmetrical perisylvian polymicrogyria, hypoplasia of the corpus callosum, dysplastic cerebellar vermis, dysmorphic basal ganglia, and severe hypoplasia of brainstem \[[@B37-brainsci-08-00145]\]. Similarly, p.(Arg214His) was initially reported in a fetus with central polymicrogyria-like cortical dysplasia, complete agenesis of the corpus callosum, and normal cerebellum \[[@B6-brainsci-08-00145]\]. It was then reported in a patient with diffuse irregular gyration and sulcation of the cortex, partial agenesis of the corpus callosum, hypoplasia of the cerebellar vermis, and globular thalami \[[@B36-brainsci-08-00145]\]. As with p.(Arg2His), these descriptions suggest variability, but with overlap in key elements of the phenotype (abnormalities of the cortex, corpus callosum, cerebellum, and basal ganglia). Some of the variability may be due to differences in the interpretation of the brain imaging. However, differences in genetic background, environmental factors, or random chance may also contribute. Oegema et al. \[[@B36-brainsci-08-00145]\] found that p.(Arg214His) caused only a mild functional deficit (incorporating into microtubule polymers at comparable levels to wild type but at a reduced rate) and subtle predicted structural effects. Mutations with relatively mild functional effects (such as p.(Arg214His) or p.(Arg2His)) may allow for other factors to influence phenotype outcome.

Mutations of the homologous Arg2 residue in other tubulin isoforms have been linked to human disease phenotypes. TUBB8 is the main beta-tubulin of oocytes. The p.(Arg2Lys) mutation in TUBB8 has been found to cause arrest of oocyte meosis \[[@B41-brainsci-08-00145]\]. The mutation is thought to affect folding of the protein as well as the assembly and stability of heterodimers. The p.(Arg2Met) mutation in TUBB8 has also been shown to cause arrest of oocyte maturation \[[@B42-brainsci-08-00145],[@B43-brainsci-08-00145]\]. TUBB4A is a brain-expressed beta-tubulin isoform. A p.(Arg2Gly) mutation in TUBB4A has been identified in a family with dystonia type 4 ('Whispering dysphonia') \[[@B44-brainsci-08-00145],[@B45-brainsci-08-00145]\]. TUBB4A p.(Arg2Trp) and p.(Arg2Gln) have been reported to cause hypomyelination with atrophy of the basal ganglia and cerebellum \[[@B46-brainsci-08-00145],[@B47-brainsci-08-00145]\]. The Arg2 of TUBB4A is part of the MREI (Met-Arg-Glu-Ile) 'auto-regulatory' domain, which is involved in controlling the amount of the beta-tubulin produced by the cell. In addition, these mutations disrupt a salt bridge Arg2 forms with Asp249 in TUBB4A \[[@B48-brainsci-08-00145]\]. This salt bridge is not predicted to occur in TUBA1A as the homologous residues are further apart.

5. Conclusions {#sec5-brainsci-08-00145}
==============

We have shown that the *TUBA1A* c.5G\>A, p.(Arg2His) mutation causes cortical, callosal, and cerebellar abnormalities that are typical of tubulinopathy-associated brain malformations. Based on its sequence context (and observation in four unrelated patients), c.5G\>A is likely to be a common recurrent mutation in *TUBA1A*. Our functional and computer modelling results suggest that p.(Arg2His) has subtle effects on microtubule function, possibly acting at the inter-dimer interface. We propose that the subtle functional effects of the mutation may allow for other factors (e.g., genetic background, environmental conditions, or random chance) to modulate outcome, explaining the mild phenotypic variability observed.

The authors would like to thank the patients, families, clinicians and scientists who contributed to this work. We would like to thank Mark I. Rees (College of Medicine, Swansea University) for donating the wild-type pRK5-TUBA1A-C-FLAG construct.

The following are available online at <http://www.mdpi.com/2076-3425/8/8/145/s1>, Supplementary File 1 containing Figure S1: Sequences from orthologs and paralogs of TUBA1A demonstrating conservation of the Arg2 residue, Figure S2: In silico RNA splicing prediction reports, Table S1: In silico predictions and population data, and the detailed clinical descriptions of the four patients with the TUBA1A p.(Arg2His) mutation; Supplementary File 2 containing Table S2: The substitution probabilities for 4548 possible substitutions in the *TUBA1A* gene based on heptanucleotide sequence context.
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![Magnetic resonance images from patients with the recurrent p.(Arg2His) TUBA1A mutation. T2-weighted axial and T1-weighted midline sagittal brain images for Patient 1 at age three years (**A**--**C**), Patient 2 at age six months (**D**--**F**), and Patient 3 at age 19 months (**G**--**I**). The images demonstrate hypoplasia and dysplasia of the cerebellar vermis (yellow arrows), thinning or partial agenesis of the corpus callosum (red arrows), globular basal ganglia with incomplete formation of the anterior limb internal capsule (white arrows), and bilateral perisylvian polymicrogyria (blue arrows). The pons is similar in size to the midbrain which suggests the pons is relatively small (**C**,**F**,**I**).](brainsci-08-00145-g001){#brainsci-08-00145-f001}

![Neuropathology from Patient 4. (**A**) The medial aspect of right cerebral hemisphere showing a thin corpus callosom with absent rostrum. (**B**) Midline sagittal section of brain stem and cerebellum showing mild hypoplasia of the cerebellar vermis. (**C**) Coronal section of the cerebral hemispheres. The corpus callosum is thinned and there is thickening of the cortex around the sylvian fissures. (**D**) Stained section of the right cerebral hemisphere revealing abnormal folding of the cortical ribbon around the sylvian fissure. (**E**) A magnified view of (**D**) demonstrating polymicrogyria around the sylvian fissure.](brainsci-08-00145-g002){#brainsci-08-00145-f002}

![In silico modelling and in vitro functional analysis of the p.(Arg2His) mutation. (**A**) Ribbon models of alpha-tubulin (green) and beta-tubulin (blue) subunits aligned in a microtubule polymer. The position of Arg2 is shown (arrow) close to the inter-dimer interface (between alpha-tubulin and the beta-tubulin of an adjacent heterodimer). The mutation is on the opposite side of TUBA1A from the binding site of guanosine-5′-triphosphate (GTP, orange). (**B**) A close-up view of the Arg2 residue (arrow) with the mutant (purple ribbon, red side chain) and wild type (green ribbon and side chain) proteins superimposed. Only mild confirmation changes are predicted around the Arg2 residue. However, additional conformational changes are predicted between residues 38 and 51 (bracket). These may affect the interaction between heterodimers. (**C**) HEK-293 cells expressing FLAG-tagged TUBA1A-R2H. The cells are stained with DAPI (4′,6-diamidino-2-phenylindole, blue), anti-FLAG- (red), and anti-alpha-tubulin (green) antibodies. The microtubules appear yellow due to the colocalisation of endogenous (green) and FLAG-tagged transgenic (red) tubulin. The arrows indicate diffuse patches of transgenic mutant tubulin (red) in the cytoplasm between the microtubules. (**D**) Control cells expressing FLAG-tagged wild-type TUBA1A have less staining for the transgenic tubulin in the cytoplasm between the microtubules.](brainsci-08-00145-g003){#brainsci-08-00145-f003}

brainsci-08-00145-t001_Table 1

###### 

Clinical features of patients with the recurrent p.(Arg2His) TUBA1A mutation.

  Patient                   1                                      2                                    3                                    4 (fetus)
  ------------------------- -------------------------------------- ------------------------------------ ------------------------------------ -----------------------------------------------------------------
  **Sex**                   Male                                   Male                                 Male                                 Male
  **OFC at Birth**          30 cm (−3.6 SD)                        34 cm (−0.9 SD)                      33 cm (−1.7 SD)                      n/a
  **Age at last review**    4 years                                32 months                            37 months                            TOP at 36 weeks gestation
  **Last OFC**              45 cm (−4.9 SD)                        43 cm (−5.9 SD)                      45 cm (−4.6 SD)                      n/a
  **Developmental delay**   Moderate                               Severe                               Moderate                             n/a
  **Seizures**              Yes (onset at 3 years)                 Yes (onset at 12 months)             No                                   n/a
  **Cerebral cortex**       Bilateral perisylvian polymicrogyria   Normal                               Normal                               Bilateral perisylvian polymicrogyria
  **White matter**          Reduced                                Reduced                              Reduced                              n/k
  **Corpus callosum**       Partial agenesis                       Thin                                 Thin                                 Short, no rostrum
  **Basal ganglia**         Dysmorphic, prominent                  Dysmorphic, prominent                Dysmorphic, prominent                n/k
  **Cerebellum**            Hypoplasia and dysplasia of vermis     Hypoplasia and dysplasia of vermis   Hypoplasia and dysplasia of vermis   Hypoplasia, Impaired lamination, rare and misaligned Purkinje
  **Brainstem**             Small pons                             Small pons                           Small pons                           Neuronal heterotopia of olivary nuclei and hypoplastic pyramids

Key: *n/a/k* = not applicable/known; OFC = occipital frontal circumference; PMG = polymicrogyria; SD = standard deviations; TOP = termination of pregnancy.

[^1]: These authors contributed equally to this work.
